This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Obstructive sleep apnoea (OSA) is a common cause of sleep disturbance, characterised by the presence of repetitive upper airway obstruction during sleep. OSA is associated with sleepiness during the day, reduced quality of life and an increased risk of cardiovascular disease. OSA can be diagnosed using several different strategies. The current reference test is fully supervised polysomnography, which is expensive and time-consuming. Other diagnostic tests, referred to as limited channel sleep studies because they include fewer parameters than polysomnography, are less resource-intensive but may also have different diagnostic performances, resulting in a difference in clinical outcomes. OBJECTIVES: To assess the clinical impact (outcome on a participant level) of a strategy where treatment follows diagnostic testing (test-treatment combination) using limited channel sleep studies compared to polysomnography in people with suspected obstructive sleep apnoea (OSA). SEARCH METHODS: We searched two databases (CENTRAL, MEDLINE) up to 11 May 2023 using search terms related to OSA and polysomnography developed by our information specialist. SELECTION CRITERIA: We included randomised controlled trials that compared any limited channel sleep studies with Level I fully supervised polysomnography in adults (aged 18 years and older) with suspected OSA. Our primary outcome was sleepiness, and our secondary outcomes were quality of life, all-cause mortality, cardiovascular events and correlating risk factors, continuous positive airway pressure (CPAP) usage, serious adverse events, and cost-effectiveness. DATA COLLECTION AND ANALYSIS: Four review authors extracted data from the included trials and assessed the risk of bias. We summarised treatment effects using random-effects meta-analyses and expressed as mean difference (MD) or standardised mean difference (SMD) with corresponding 95% confidence intervals (CI) where possible. We used GRADE to assess the certainty of the evidence. MAIN RESULTS: = 39%; 2 trials, 573 participants). Additionally, there is low-certainty evidence that they may result in little to no difference in cardiovascular events and correlating risk factors. For quality of life, CPAP adherence, serious adverse events and cost-effectiveness, the evidence is very uncertain. None of the included trials reported on all-cause mortality. AUTHORS' CONCLUSIONS: Level III sleep studies may result in little to no difference in clinical outcomes when compared to Level 1 sleep studies in people with suspected OSA. Level IV sleep studies may not increase sleepiness and may result in little to no difference in cardiovascular events and correlating risk factors compared to Level I sleep studies; the evidence was too uncertain to make statements for other outcomes. Overall, the body of evidence was limited, therefore more trials making this comparison are necessary, as are trials with a longer follow-up duration.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Doorn et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: